Corindus has announced today global launch of a new set of automated robotic movements in the technIQ Series designed for the CorPath GRX system. The company received 510(k) clearance from the US Food and Drug Administration (FDA) for new software automation that provides predictable and consistent movements to aid in advanced device manipulation during complex coronary and peripheral procedures.
Jean Fajadet, the co-director of interventional cardiology at Clinique Pasteur, Toulouse, France, performed the first-in-human coronary procedures using the new automated movements, which replicate manual techniques of interventionalists. The procedures demonstrated how the new movements can help to reduce procedure time associated with wire and device manipulation and drive standardisation in quality of care by offering advanced techniques to all physicians.
“This new software algorithm gives the operator new possibilities to advance and facilitate treatment, especially with complex lesions,” said Fajadet. “I am pleased with the success of using the automated moves and am honored to play a role in the advancement of robotic technology that will make interventional procedures more efficient and safer for our patients.”
In 2018, Corindus received CE mark and FDA clearance for an automated technique called Rotate on Retract (RoR). RoR was the first automated robotic movement in the technIQ Series and has demonstrated the potential to significantly reduce wiring time. The latest global introduction and FDA clearance for the technIQ Series provides physicians with four additional automated robotic movements that aid with complex tasks such as crossing lesions, navigating tortuosity, and precisely measuring the anatomy for appropriate device size selection.
“The new technIQ movements mark the next phase in the evolution of robotic-assisted intervention and a vital step toward the advancement of our technology,” said Wayne Markowitz, executive vice president and head of Corindus. “Automating more movements used in cardiovascular intervention will allow physicians to focus their attention on overall case strategy while equipping them with advanced techniques for navigating the vasculature.”
Corindus is a Siemens Healthineers company, following a merger in 2019.
